[Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer]

Gan To Kagaku Ryoho. 1999 Mar;26(4):535-8.
[Article in Japanese]

Abstract

We investigated the relationship between delayed emesis caused by cisplatin (CDDP) based chemotherapy and plasma levels of serotonin, 5-hydroxy-indoleacetic acid (5-HIAA), and substance P in two patients with small cell lung cancer. In each of the cases, we used the 5-HT3 receptor antagonist ramosetron every morning on day 1-4 of the chemotherapy. In case 1, plasma levels of serotonin were low, whereas substance P levels increased since 24 hours after the injection of CDDP. The increase in substance P levels paralleled the onset of vomiting. In this case, however, substance P levels decreased and yet vomiting occurred. Similarly, in case 2, plasma levels of serotonin were low, whereas substance P levels increased since 24 hours. The increase in plasma levels of substance P and the onset of vomiting were observed at the same time 2-3 days after cisplatin administration. In this case, however, vomiting was not observed during the 5 days when the substance P was highest. Therefore, we suggested that substance P was closely associated with CDDP-induced delayed emesis, though some chemical mediators other than substance P might also be related to the emesis.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzimidazoles / therapeutic use*
  • Carcinoma, Small Cell / blood
  • Carcinoma, Small Cell / drug therapy
  • Cisplatin / adverse effects*
  • Humans
  • Hydroxyindoleacetic Acid / blood
  • Lung Neoplasms / blood
  • Lung Neoplasms / drug therapy
  • Male
  • Serotonin / blood
  • Serotonin Antagonists / therapeutic use*
  • Substance P / blood
  • Substance P / physiology*
  • Vomiting, Anticipatory / etiology*

Substances

  • Benzimidazoles
  • Serotonin Antagonists
  • Serotonin
  • Substance P
  • Hydroxyindoleacetic Acid
  • ramosetron
  • Cisplatin